Infectious Disease Clinical Trials

Statistical methods in infectious disease trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All infectious disease trials

903 results

• Efficacy of ClōSYS® Sensitive Fluoride Toothpaste and ClōSYS® Sensitive Rinse Regimen on MGI, PI and BOP: Complete Statistical AnalysisIndependent statistical analysis of Efficacy of ClōSYS® Sensitive Fluoride Toothpaste and ClōSYS® Sensitive Rinse Regimen on MGI, PI and BOP: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 60NCT05258721
• Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016): Complete Statistical AnalysisIndependent statistical analysis of Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016): primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2/3Results postedn = 1,224NCT03537274
• Efficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax Malaria: Complete Statistical AnalysisIndependent statistical analysis of Efficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax Malaria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 22NCT04709692
• Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults: Complete Statistical AnalysisIndependent statistical analysis of Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults: primary endpoint results,…Phase 3Results postedn = 55NCT01967940
• Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice: Complete Statistical AnalysisIndependent statistical analysis of Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 403NCT00963508
• Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria: Complete Statistical AnalysisIndependent statistical analysis of Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 15NCT03580044
• eHealth Evidence-based Intervention (EBI) for Latino Youth in Primary Care: Complete Statistical AnalysisIndependent statistical analysis of eHealth Evidence-based Intervention (EBI) for Latino Youth in Primary Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03009539).Phase NAResults postedn = 921NCT03009539
• EHPOCIndependent statistical analysis of Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04793750).Phase NAResults postedn = 224NCT04793750
• ELEVATEIndependent statistical analysis of Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures: primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 292NCT00678587
• Eltrombopag Phase III Study In Chinese Chronic ITP Patients: Complete Statistical AnalysisIndependent statistical analysis of Eltrombopag Phase III Study In Chinese Chronic ITP Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01762761).Phase 3Results postedn = 155NCT01762761
• EMPACTAIndependent statistical analysis of the randomized phase 3 EMPACTA trial evaluating tocilizumab in hospitalized participants with COVID-19 pneumonia, including trial design, endpoints, statistical methodology, reported safety data, and educational interpretation.Phase 3Results postedn = 377NCT04372186
• Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms: Complete Statistical AnalysisIndependent statistical analysis of Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00778648).Phase NAResults postedn = 543NCT00778648
• endTBIndependent statistical analysis of the phase 3 endTB trial (NCT02754765), evaluating newly approved drugs for multidrug-resistant tuberculosis, including trial design, the week 73 efficacy endpoint, planned statistical analysis, and interpretation.Phase 3n = 754NCT02754765
• endTB-QIndependent statistical analysis of the phase 3 endTB-Q trial evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance.Phase 3n = 323NCT03896685
• ENDURANCE-2Independent statistical analysis of A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection: primary endpoint results, effect estimate with confidence…Phase 3Results postedn = 304NCT02640482
• ENDUREIndependent statistical analysis of A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis…Phase 2Results postedn = 251NCT05375760
• Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B: Complete Statistical AnalysisIndependent statistical analysis of Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 669NCT00410072
• EpHectIndependent statistical analysis of Clinical Performance of the Gedea Pessary in Adult Women With Vulvovaginal Candidiasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 26NCT05507333
• EPIC-PEDSA detailed statistical analysis of EPIC-PEDS, a phase 3 single-group study of nirmatrelvir/ritonavir in patients under 18 years of age with COVID-19 who are not hospitalized but are at risk for severe…Phase 3n = 160NCT05261139
• EPIC-SRIndependent statistical analysis of EPIC-SR (NCT05011513), the randomized, placebo-controlled phase 2/3 trial of nirmatrelvir plus ritonavir in standard-risk COVID-19, covering the log-rank primary analysis, logistic-regression odds ratios, negative binomial modelling and serious…Phase 2/3Results postedn = 1,440NCT05011513
• Epidemiology and Prevention of Methicillin Resistant Staphylococcus Aureus (MRSA) Transmission in the Community: Complete Statistical AnalysisIndependent statistical analysis of Epidemiology and Prevention of Methicillin Resistant Staphylococcus Aureus (MRSA) Transmission in the Community: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 223NCT00966446
• EPT and MSMIndependent statistical analysis of Expedited Partner Therapy and the HIV Prevention Cascade: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04553211).Phase NAResults postedn = 663NCT04553211
• ERADICATE HpIndependent statistical analysis of ERADICATE Hp - Treating Helicobacter Pylori With RHB-105: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01980095).Phase 3Results postedn = 119NCT01980095
• ESCAPEIndependent statistical analysis of the ESCAPE phase 3 trial evaluating high-titer COVID-19 convalescent plasma versus standard plasma in COVID-19. Includes trial design, endpoints, planned statistical methodology, and interpretation of the registry record.Phase 3n = 45NCT04361253
• ESCAPeIndependent statistical analysis of Extended Steroid in Use in Community Acquired Pneumonia (CAP)(e): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01283009).Phase 3Results postedn = 584NCT01283009
• ESPRITComplete statistical analysis of ESPRIT, the randomized phase 3 trial of recombinant interleukin-2 in HIV-positive patients receiving antiretroviral therapy, including time-to-event, longitudinal CD4, categorical, safety, and statistical interpretation.Phase 3Results postedn = 4,150NCT00004978
• Etoposide in Patients With COVID-19 Infection: Complete Statistical AnalysisIndependent statistical analysis of Etoposide in Patients With COVID-19 Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04356690).Phase 2Results postedn = 8NCT04356690
• EVA-VRS01Independent statistical analysis of A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuated hRSV Vaccine rBCG-N-hRSV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1Results postedn = 24NCT03213405
• EVADEComplete statistical analysis of the randomized phase 2/3 EVADE trial of ADG20 for the prevention of COVID-19, including trial design, primary and secondary endpoints, risk differences, hazard ratios, statistical methodology, safety, and…Phase 2/3Results postedn = 2,582NCT04859517
• Evaluating Immune Response to Seasonal FluMist in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Evaluating Immune Response to Seasonal FluMist in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01673425).Phase NAResults postedn = 5NCT01673425
• Evaluating the Effect of Chronic Antihypertensive Therapy on Vasopressor Dosing in Septic Shock: Complete Statistical AnalysisIndependent statistical analysis of Evaluating the Effect of Chronic Antihypertensive Therapy on Vasopressor Dosing in Septic Shock: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 133NCT02884011
• Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection: Complete Statistical AnalysisIndependent statistical analysis of Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection: primary endpoint results, effect…Phase 3Results postedn = 262NCT01482767
• Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children: Complete Statistical AnalysisIndependent statistical analysis of Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children: primary endpoint results, effect estimate with…Phase 1Results postedn = 45NCT03387137
• Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations: Complete Statistical AnalysisIndependent statistical analysis of Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 10NCT01517529
• Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza: Complete Statistical AnalysisIndependent statistical analysis of Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 329NCT02287467
• Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).: Complete Statistical AnalysisIndependent statistical analysis of Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 7NCT05997277
• Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women: Complete Statistical AnalysisIndependent statistical analysis of Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women: primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 3,224NCT03164564
• Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.: Complete Statistical AnalysisIndependent statistical analysis of Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1Results postedn = 51NCT04915768
• Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults: Complete Statistical AnalysisIndependent statistical analysis of Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults: primary endpoint results, effect estimate…Phase 1Results postedn = 124NCT03387150
• Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women: Complete Statistical AnalysisIndependent statistical analysis of Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 956NCT01494038
• Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 1Results postedn = 40NCT02485912
• Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 1,806NCT01545375
• Evaluation of Aerosol in a Dental Clinic: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Aerosol in a Dental Clinic: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04659928).Phase 4Results postedn = 41NCT04659928
• Evaluation of Diagnostic HIV Ag/Ab Combo Assay: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Diagnostic HIV Ag/Ab Combo Assay: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00933933).Phase 3Results postedn = 635NCT00933933
• Evaluation of Effectiveness of the Treatment After Repeated Administration of Klacid®SR: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Effectiveness of the Treatment After Repeated Administration of Klacid®SR: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 3,130NCT01130883
• Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu: primary endpoint results, effect estimate with…Phase 3Results postedn = 341NCT01448057
• Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 4Results postedn = 506NCT00684671
• Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002): Complete Statistical AnalysisIndependent statistical analysis of Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1Results postedn = 9NCT02392494
• Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301): Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301): primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 185NCT00704717
• Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 389NCT00856297

← All therapeutic areas